With the firm's focus on enabling immediate detection of treatment response in support of precision medicine across cancer therapies and emerging immunotherapies, the Lodestone effort is to improve patient outcomes by helping medical professionals make treatment decisions earlier. The judgment is that capacity to understand the individual patient's response on a cellular level xould/will guide physicians to take the best informed course of action, Management describe the firm as Accelerating Drug Discovery, identifying the firm's focus as in vivo biomarking monitoring. Lodestones biomarker monitoring technology provides signals of efficacy to guide the development of emerging immunotherapies during preclinical development.
